For drug launch in the United States.
Czech Republic, Romania, Serbia among potential targets.
Upside potential remains high, though.
For parent company Deutsche Telekom.
OTP decline in May has a lot to do with popularity.
For its incentive programme.
That is more than EUR 3.8 million.
Recommendations for Esmya approved by CHMP.
Fonte Viva was established in 2002.
To HUF 5,470 from HUF 5,695.
Shareholders must be happier than life insurance policy holders.
Esmya may remain on markets but with restrictions.
For HUF 70 million, for incentive programme.
Offers a 26% upside potential.
OTP in tip-top shape.
CEO leaves group in top shape.
After release of Q1 earnings report.
It's a matter of perspective, really.
Analysts are split over after-tax profit.